Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,060.86 USD
+5.29 (0.50%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $1,060.80 -0.06 (-0.01%) 5:22 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
REGN 1,060.86 +5.29(0.50%)
Will REGN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for REGN
Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
HRMY or REGN: Which Is the Better Value Stock Right Now?
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Other News for REGN
Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat
Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors
REGN Crosses Above Average Analyst Target
TD Cowen Keeps Their Buy Rating on Regeneron (REGN)
Piper Sandler Reaffirms Their Buy Rating on Regeneron (REGN)